ADC Development Grows More Complex — SPR Insights Bring Clarity

Antibody-drug conjugates continue to gain momentum as targeted therapeutics, but their complexity demands analytical tools that can keep pace with development challenges. This piece explores how surface plasmon resonance (SPR) supports a deeper understanding of ADC behavior by enabling real-time analysis of antibody–antigen interactions throughout development. Learn how binding kinetics and affinity can shift with changes in conjugation strategy, linker chemistry, drug–antibody ratio, and assay conditions such as pH. The discussion also highlights approaches for characterizing anti-drug antibodies, including weak or transient interactions that are difficult to capture with traditional methods.

By grounding the science in real-world data and application examples, you can gain practical insight into how SPR can help generate reliable, reproducible results and inform better decisions when advancing ADC candidates toward the clinic.